Information whose publication might prejudice the commercial interests of individuals or companies to an unreasonable degree. The Agency cannot disclose commercially confidential information unless there is an overriding public interest in disclosure.
More information can be found in the 'Procedure for European Union guidelines and related documents within the pharmaceutical legislative framework'.